European Journal of Artificial Intelligence and Machine Learning
Vol 5 | Issue 2 | March 2026
ISSN 2796-0072

RESEARCH ARTICLE

GAMP 5 Validation of AI/ML in Sterile Manufacturing

Aniruddha Umeshchandra Dhole*

ABSTRACT

This examines the essential role of Good Automated Manufacturing Practice (GAMP) 5 in providing a formal, structured framework for validating artificial intelligence (AI) and machine learning (ML) systems within sterile pharmaceutical manufacturing facilities. AI/ML technologies offer significant potential to revolutionize sterility assurance, process optimization, and compliance monitoring, their inherent non-deterministic nature poses a critical challenge to traditional deterministic validation methods. Th research leverages the risk-based lifecycle perspective of GAMP 5, integrating it with regulatory expectations and technical best practices, to demonstrate a viable path where compliance and technological innovation can coexist. The findings underscore the necessity of robust validation practices that explicitly integrate data integrity, explainability (transparency), and continuous monitoring to ensure that AI/ML systems remain secure, auditable, and reliable in highly critical sterile manufacturing environment.

Keywords: AI/ML validation, GAMP 5, quality management system (QMS), sterile manufacturing.

Submitted: November 05, 2025

Published: March 06, 2026

10.24018/ejai.2026.5.2.1093

Design Quality Assurance, Flex, United States of America.

Corresponding Author:
e-mail: aniruddha.dhole96@gmail.com

1. Introduction

Sterile pharmaceutical manufacturing one of the most rigorously regulated sectors the healthcare industry, given its direct and critical impact on patient safety. Sterility assurance is paramount and failure in this area can lead to severe health consequences or product recall. The recent emergence of artificial intelligence (AI) and machine learning (ML) technologies has opened new avenues for achieving heightened efficiency, enabling sophisticated predictive analytics, and ultimately enhancing sterility assurance levels [1]–[9].

1.1. Research Gap and Significance

Despite the revolutionary potential of AI/ML, these adaptive data-driven technologies fundamentally challenge the industry's traditional, fixed validation approaches. xisting frameworks often struggle to address the dynamic nature and non-determinism of self-learning models. This introduces a significant research gap: the need for a systematized, regulatorily accepted framework specifically designed for validating complex AI/ML systems in high-risk environments, such as sterile manufacturing. Without a clear framework, implementing these innovative technologies risks noncompliance with regulatory requirements [1].

Regulators, including the United States Food and Drug Administration (FDA) and European Medicines Agency (EMA), mandate the implementation of structured frameworks to ensure compliance and reliability of all computerized systems. Good Automated Manufacturing Practice (GAMP) 5, particularly its second edition (released in 2022), serves as the leading guideline for AI/ML lifecycle management in the pharmaceutical industry. This guideline offers necessary foundation for integrating these new technologies into GxP environments [1].

1.2. Paper Objective and Contribution

The application of harmonized guideline is highly relevant to current trends in the pharmaceutical industry, particularly those related to novel approaches to sterility assurance. Regulators, including the United States Food and Drug Administration (FDA) and European Medicines Agency (EMA), mandate the implementation of structured frameworks to ensure compliance and reliability of all computerized systems. Good Automated Manufacturing Practice (GAMP) 5, particularly



Fig. 1. Risk-based validation matrix.

its second edition (released in 2022), serves as the leading guideline for AI/ML lifecycle management in the pharmaceutical industry. This guideline offers necessary foundation for integrating these new technologies into GxP environments [1].

2. Regulatory Background and GAMP 5 Overview

GAMP 5: A Risk-Based Approach to Compliant GxP Computerized Systems is a globally recognized guideline developed by the International Society of Pharmaceutical Engineering (ISPE). It provides a risk-based model for validating computerized systems in regulated environments. The fundamental principles of GAMP 5, including its emphasis on lifecycle management, scalable evidence, and data integrity, make it uniquely relevant for addressing the complexities of AI/ML applications. The second edition specifically addresses the rising importance of higher-order analytics in drug production by introducing new appendices on topics AI/ML lifecycle management, cloud computing, and advanced data integrity measures [1]–[3].

2.1. Key Regulatory Alignment

For sterile manufacturing, computerized systems must adhere to GAMP 5 guidelines remain consistent with critical global regulations to ensure system integrity and process control. These include [1]:

- *21 CFR Part 11 (FDA):* Focuses on the requirements for electronic records and signatures, mandating controls to ensure system performance, reproducibility, and integrity [1].
- *EU GMP Annex 11 (EMA):* Provides equivalent regulatory guidance for computerized systems within the European Union [1].
- *ICH Q9 (Quality Risk Management):* Requires a systematic approach to quality risk management, a core principle GAMP 5 through its risk-based approach [1].

Collectively, these standards demand documented evidence that the computerized system, including any embedded AI/ML model, performs consistently, ensures the integrity of its data, and is subject to strict change control [1].

3. AI/ML in Sterile Manufacturing

The utility of AI and ML in sterile manufacturing is expanding, offering new methods to enhance the assurance of sterility and increase process reliability. These applications focus on transitioning from reactive quality control to predictive and preventive quality assurance [4]–[8].

As illustrated in Fig. 2, the key application areas include:

- *Predictive Maintenance:* AI models can analyze sensor data from sterilization equipment (autoclaves or filling lines) to predict potential equipment failure before it occurs. This proactive approach helps avoid costly downtime and critically mitigates the risk of a breach in sterility assurance that could compromise product quality [4]–[8].
- *Automated Deviation Detection and Anomaly Detection:* ML algorithms are powerful tools for real-time quality control. The utility of AI and ML in sterile manufacturing is expanding, offering new methods to enhance the assurance of sterility and increase process reliability. These applications focus on transitioning from reactive quality control to predictive and preventive quality assurance [4]–[8].
- *Real-Time Monitoring and Adaptive Control:* AI can continuously monitor critical process parameters (CPPs) and critical quality attributes (CQAs). In advanced applications, Adaptive Control systems can use ML to make minor instantaneous adjustments to manufacturing parameters to maintain optimal process conditions, ensuring the product remains within the validated state [1].

These applications offer profound benefits but require sophisticated validation strategies that can manage the dynamic nature of machine-learning models and their continually evolving predictions.



Fig. 2. AI/ML in sterile manufacturing.



Fig. 3. GAMP 5 lifecycle phases adapted for AI/ML validation in sterile manufacturing [1], [3].

4. Validation Challenges in AI/ML

The validation of AI/ML systems presents distinct challenges that differ significantly from those of traditional deterministic models. In a regulated setting, these challenges are amplified by the critical nature of sterile manufacturing processes.

- *Non-Determinism and Reproducibility:* Unlike classical software, AI/ML models are dynamic and evolve as they are exposed to new data. This nondeterministic action presents challenges to reproducibility, particularly because traditional verification relies on predictably behaved models.
- *Explainability (Model Transparency):* The complexity of many ML models, often referred to as 'black boxes, makes it challenging to understand and explain how a specific output or decision s reached. Regulators expect validation includ mechanisms for model transparency, ensuring that critical decisions affecting product quality can be auditable and justified [1].
- *Data Quality and Integrity:* AI/ML models are as reliable as the data used to train them. In sterile manufacturing, validation must address system functionality as well as the integrity, traceability, and quality of the large-scale training datasets used. Poor data quality, bias, and gaps can lead to fundamental flawed systems.

the importance of sterility preservation, regulators expect the validation process to integrate data integrity checks, provide robust audit trails for all model updates, and include continuous, ongoing monitoring of system performance [1]–[3].

5. Applying GAMP 5 to AI/ML Validation

The GAMP 5 lifecycle-based approach provides a robust and structured framework for addressing the unique validation challenges posed by AI/ML in sterile manufacturing. The core GAMP 5 lifecycle phases must be adapted to specifically accommodate the dynamic nature of machine learning (Fig. 3) [1], [3]–[5].

5.1. Adapted GAMP 5 Lifecycle Phases

The GAMP 5 lifecycle-based approach provides a robust and structured framework for addressing the unique validation challenges posed by AI/ML in sterile manufacturing. The core GAMP 5 lifecycle phases must be adapted to specifically accommodate the dynamic nature of machine learning (see Fig. 3).

1. Concept Phase: Define the intended use, scope, specific regulatory requirements, and risk profile of the AI/ML system. The level of risk dictate the intensity of the subsequent validation effort [1].
2. *Project Phase:* Establish comprehensive User Requirements Specifications (URS), focusing on model performance metrics (e.g., accuracy and precision) and explainability requirements. This phase includes design qualification and meticulous model documentation, detailing the algorithms, training data, and environment.
3. *Operation Phase:* Continuous monitoring of model performance against established metrics to detect model drift or degradation. This phase also requires a stringent process of change control and timely re-examination/re-validation whenever the model is retrained or updated.
4. *Retirement Phase:* Ensure secure and compliant decommissioning of the system, including requirements for long-term data retention and archiving of critical model documentation.

5.2. The Risk-Based Approach

Central to GAMP 5 is the principle of risk-based validation, which determines the intensity of the validation effort based on the impact on product quality and patient safety. Companies focus greater validation rigor high-risk applications [1], [3].

- A sterile monitoring system or automated quality control system, which directly impacts the release of sterile products, warrants a validation intensity level of four (High Risk).
- For instance, decision-support tools that carry low risk should not be highly validated compared with sterility monitoring systems, where high levels of risk are involved.

The risk-based matrix shown in Fig. 1 provides a visual representation of this principle.



Fig. 4. GAMP 5 Lifecycle phases adapted for AI/ML validation in sterile manufacturing [1], [3].

5.3. *Data Integrity MLOps Checkpoints*

As illustrated in Fig. 4, strong data-integrity checkpoints are mandatory throughout the entire process [2], [3].

- *Data Governance:* Establishing clear controls, traceability, and security over data.
- *MLOps/Quality Management System (QMS) Integration:* Leverage MLOps to automate and manage the deployment pipeline, ensuring that all model updates and configurations are recorded via robust audit trails and backups.
- *Validated State Maintenance:* Implementing regular audits, chang management protocols, and personnel training to ensure the AI/ML system remains in a validated state [1].

6. Discussion

The integration of GAMP 5 into the validation of AI/ML systems in sterile manufacturing strikes a crucial balance between maintaining rigorous regulatory compliance and fostering technological innovation. The GAMP 5 framework inherently ensures that AI/ML applications remain transparent, auditable, and aligned with GxP quality standards [1], [3].

However, the industry still faces several material challenges, including model transparency, validation rigor, and implementation governance, which are widely recognized across AI applications in pharmaceutical systems [10]:

- Regulatory Harmonization: A current difficulty is the absence of globally harmonized prescriptive regulations specifically targeting the validation of autonomous, self-learning AI in pharmaceutical manufacturing [1].
- *Case Study Limitations:* The number of published real-world case studies detailing the validation of high-risk AI/ML systems (e.g., sterility monitoring) in sterile manufacturing is limited, making the application of GAMP 5′s principles more challenging in practice [1], [3].
- *Technical Best Practices:* Industry-wide collaboration is still needed to establish standardized best practices for implementing continuous monitoring and scientifically sound methods for measuring and documenting the explainability of complex ML models.

Industry-wide collaboration is required to establish consistent standards and practices, especially concerning the technical details of continuous monitoring and explainability of ML systems. Despite these limitations, GAMP 5 provides a robust adaptable structure that organizations can ue to develop AI/ML validation strategies [1], [3].

7. Conclusion

The adoption of AI and ML is transformative for sterile pharmaceutical production, effective risk-based validation methods must guide their implementation. The risk-based, lifecycle-centric approach outlined in GAMP 5 is highly effective in delivering compliance while also allowing for innovation. By systematically consolidating principles of data integrity and model explainability stringent ongoing monitoring and tracking, organizations can harness AI/ML to increase sterility assurance without violating regulatory mandates. Future work will require industry to build case-specific evidence and reconcile international standards to advance the practical application of AI/ML validation in this critical sector [1]–[3].

Conflict of Interest

The authors declare that they do not have any conflict of interest.

References

[1] Niazi SK. Regulatory perspectives for AI/ML implementation in pharmaceutical GMP environments. *Pharmaceuticals*. 2025 Jun 16;18(6):901.
[2] Sembiring MH, Novagusda FN. Enhancing data security resilience in AI-driven digital transformation: exploring industry challenges and solutions through ALCOA+ principles. *Acta Inform Med*. 2024;32(1):65.
[3] Gokulakrishnan D, Venkataraman S. Ensuring data integrity: best practices and strategies in pharmaceutical industry. *Intell Pharm*. 2024 Sep 26;3(4):296–303.
[4] Vora LK, Gholap AD, Jetha K, Thakur RR, Solanki HK, Chavda VP. Artificial intelligence in pharmaceutical technology and drug delivery design. *Pharmaceutics*. 2023 Jul 10;15(7):1916.
[5] Kolluri S, Lin J, Liu R, Zhang Y, Zhang W. Machine learning and artificial intelligence in pharmaceutical research and development: a review. *AAPS J*. 2022 Jan 4;24(1):19.
[6] Al-Hourani S, Weraikat D. A systematic review of artificial intelligence (AI) and machine learning (ML) in pharmaceutical supply chain (PSC) resilience: current trends and future directions. *Sustainability*. 2025 Jul 19;17(14):6591.
[7] Jena GK, Patra CN, Jammula S, Rana R, Chand S. Artificial intelligence and machine learning implemented drug delivery systems: a paradigm shift in the pharmaceutical industry. *J Bio-X Res*. 2024 Oct 23;7:0016.
[8] Fu C, Chen Q. The future of pharmaceuticals: artificial intelligence in drug discovery and development. *J Pharm Anal*. 2025 Feb 26;15(8):101248.
[9] Rakočević T, Markovic M. Assessing the impact of AI: the case of the pharmaceutical industry. *Eur J Bus Manage Res*. 2024 Sep 20;9(5):70–5.
[10] Blanco-Gonzalez A, Cabezon A, Seco-Gonzalez A, Conde-Torres D, Antelo-Riveiro P, Pineiro A, *et al.* The role of AI in drug discovery: challenges, opportunities, and strategies. *Pharmaceuticals*. 2023 Jun 18;16(6):891.